Quantum BioPharma Gives Licensee Unbuzzd Until 2027 to Repay, Raises Stake to 19.87%

Quantum BioPharma has loosened the financial terms of its relationship with licensee Unbuzzd Wellness, giving the company until 31 December 2027 to repay a loan and letting interest accrue rather than be paid currently. The change is disclosed in Quantum's management discussion and analysis for the quarter and nine months to 30 September 2026, dated 12 November.

The restructuring came with two other adjustments. Quantum cancelled a warrant certificate that Unbuzzd had held, which carried anti-dilution protection. Quantum also bought 1.5 million new Unbuzzd shares at C$0.20 each in a private placement, taking its ownership of the licensee to 19.87%. The filing as summarised does not give the total loan balance, the interest rate or the value of the deferred interest, so the scale of Quantum's exposure cannot be read from the facts available.

Taken together, the moves leave Quantum as both creditor and a larger shareholder in a commercial partner, with repayment pushed back by a further period. How the loan will be settled is not addressed in the information reviewed.

Separately, Quantum's Class B shares stopped trading on the Canadian Securities Exchange on 4 September 2026. They remain listed on Nasdaq, which is now the company's only trading venue for the stock. No reasons for the delisting were provided in the material available.

The MD&A also states that Lucid-MS, the company's lead asset for multiple sclerosis, is still preclinical. No development timelines or data accompanied that statement, so the update implies no near-term regulatory filings.